Tagrisso + Imfinzi + Enhertu + Imjudo

**Tagrisso + Imfinzi + Enhertu + Imjudo** is an experimental four-drug combination therapy primarily investigated for advanced non-small cell lung cancer (NSCLC), particularly in patients with EGFR-mutated tumors progressing after prior EGFR tyrosine kinase inhibitor (TKI) therapy. It combines **Tagrisso (osimertinib)**, a third-generation irreversible small-molecule EGFR TKI that selectively inhibits EGFR-mutant kinases including T790M; **Imfinzi (durvalumab)**, a human IgG1 monoclonal antibody blocking PD-L1 to restore anti-tumor T-cell activity; **Enhertu (trastuzumab deruxtecan)**, an antibody-drug conjugate (ADC) comprising a HER2-directed antibody linked to a topoisomerase I inhibitor payload for targeted delivery; and **Imjudo (tremelimumab)**, a human IgG2 monoclonal antibody targeting CTLA-4 to enhance T-cell priming and activation. Developed by AstraZeneca (Tagrisso, Imfinzi, Imjudo) and Daiichi Sankyo/AstraZeneca (Enhertu), this regimen aims to address multiple resistance mechanisms in EGFR-mutant NSCLC through synergistic EGFR inhibition, HER2 targeting, and dual immune checkpoint blockade.